dBET6 - 98%, high purity , CAS No.1950634-92-0, Inhibitor of bromodomain containing 4

Item Number
D414163
Grouped product items
SKUSizeAvailabilityPrice Qty
D414163-5mg
5mg
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$137.90
D414163-10mg
10mg
3
$206.90
D414163-25mg
25mg
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$414.90
D414163-50mg
50mg
3
$741.90

PROTAC

Basic Description

SynonymsCHEBI:189651 | VALRUBICIN [ORANGE BOOK] | A935629 | EN300-23308290 | s8762 | AKOS037653363 | f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)-N-(8-(2-((2-(2,6- | BD177448 | dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4- | US11059801, Compound dBET6 | dBET6 | dbet
Specifications & PurityMoligand™, ≥98%
Biochemical and Physiological MechanismsdBET6 is a highly cell-permeable PROTAC degrader of BET bromodomains with an IC50 of 14 nM for BRD4 binding. dBET6 also induces c-MYC downregulation and apoptosis.
Storage TempStore at -20°C
Shipped InIce chest + Ice pads
GradeMoligand™
Action TypeINHIBITOR
Mechanism of actionInhibitor of bromodomain containing 4
Product Description

Information

dBET6 is a highly cell-permeable PROTAC degrader of BET bromodomains with an IC50 of 14 nM for BRD4 binding. dBET6 also induces c-MYC downregulation and apoptosis .


Targets

BRD4 14 nM


In vitro

dBET6 is a highly cell-permeable degrader of BET bromodomains. It is potent in most cancer cell lines. dBET6 features highly increased cellular potency with evident degradation in the sub-nanomolar range. Treatment with 100 nM dBET6 leads to degradation of BRD4 after 1 hr, prompting subsequent downregulation of c-MYC and induction of apoptosis. dBET6 disrupts global productive transcription elongation. dBET6 treatment leads to a widespread decrease in steady-state mRNA levels, but observed an incommensurate impact on expression of members of the core regulatory circuitry of leukemogenic transcription factors. The collapse of the core transcriptional machinery prompted by BET degradation precedes a robust apoptotic response, of apparent translational significance.


In vivo

dBET6 is well tolerated. Upon dBET6 treatment, a significant reduction of leukemic burden is observed in a disseminated mouse model of T-ALL. Moreover, mice treated with dBET6 (7.5 mg/kg BID) exhibits a significant survival benefit compared to mice treated with vehicle control or JQ1 (20 mg/kg QD).


Cell Research(from reference)

Cell lines:MOLT4 cells deficient in CRBN expression 

Concentrations:0.05, 0.1, 0.5, 1 μM 

Incubation Time:3 hr 

AI Insight

Product Properties

ALogP4.8
HBD Count3
Rotatable Bond16

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Names and Identifiers

Pubchem Sid504772951
Pubchem Sid Urlhttps://pubchem.ncbi.nlm.nih.gov/substance/504772951
IUPAC Name 2-[(9S)-7-(4-chlorophenyl)-4,5,13-trimethyl-3-thia-1,8,11,12-tetrazatricyclo[8.3.0.02,6]trideca-2(6),4,7,10,12-pentaen-9-yl]-N-[8-[[2-[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl]oxyacetyl]amino]octyl]acetamide
INCHI InChI=1S/C42H45ClN8O7S/c1-23-24(2)59-42-35(23)37(26-13-15-27(43)16-14-26)46-29(38-49-48-25(3)50(38)42)21-33(53)44-19-8-6-4-5-7-9-20-45-34(54)22-58-31-12-10-11-28-36(31)41(57)51(40(28)56)30-17-18-32(52)47-39(30)55/h10-16,29-30H,4-9,17-22H2,1-3H3,(H,44,53)(H,45,54)(H,47,52,55)/t29-,30?/m0/s1
InChi Key JGQPZPLJOBHHBK-UFXYQILXSA-N
Canonical SMILES CC1=C(SC2=C1C(=NC(C3=NN=C(N32)C)CC(=O)NCCCCCCCCNC(=O)COC4=CC=CC5=C4C(=O)N(C5=O)C6CCC(=O)NC6=O)C7=CC=C(C=C7)Cl)C
Isomeric SMILES CC1=C(SC2=C1C(=N[C@H](C3=NN=C(N32)C)CC(=O)NCCCCCCCCNC(=O)COC4=CC=CC5=C4C(=O)N(C5=O)C6CCC(=O)NC6=O)C7=CC=C(C=C7)Cl)C
PubChem CID 121427831
Molecular Weight 841.37

Certificates(CoA,COO,BSE/TSE and Analysis Chart)

C of A & Other Certificates(BSE/TSE, COO):
Analytical Chart:

Find and download the COA for your product by matching the lot number on the packaging.

2 results found

Lot NumberCertificate TypeDateItem
G2227829Certificate of AnalysisJun 12, 2022 D414163
G2227841Certificate of AnalysisJun 12, 2022 D414163

Safety and Hazards(GHS)

Pictogram(s) GHS06,   GHS08
Signal Danger
Hazard Statements

H301:Toxic if swallowed

H360:May damage fertility or the unborn child

Precautionary Statements

P280:Wear protective gloves/protective clothing/eye protection/face protection.

P321:Specific treatment (see ... on this label).

P405:Store locked up.

P501:Dispose of contents/container to ...

P264:Wash hands [and …] thoroughly after handling.

P270:Do not eat, drink or smoke when using this product.

P330:Rinse mouth.

P203:Obtain, read and follow all safety instructions before use.

P301+P316:IF SWALLOWED: Get emergency medical help immediately.

P318:if exposed or concerned, get medical advice.

Related Documents

Reviews

Customer Reviews

References

1. Winter GE, Mayer A, Buckley DL, Erb MA, Roderick JE, Vittori S, Reyes JM, di Iulio J, Souza A, Ott CJ et al..  (2017)  BET Bromodomain Proteins Function as Master Transcription Elongation Factors Independent of CDK9 Recruitment..  Mol Cell,  67  (1): (5-18.e19).  [PMID:28673542] [10.1021/op500134e]

Solution Calculators